Details

Autor(en) / Beteiligte

• Miyoshi, Toru
• Kohno, Kunihisa
• Asonuma, Hirohiko
• Sakuragi, Satoru
• Nakahama, Makoto
• Kawai, Yusuke
• Uesugi, Tadahisa
• Oka, Takefumi
• Munemasa, Mitsuru
• Takahashi, Natsuki
• Mukohara, Naoki
• Habara, Seiji
• Koyama, Yasushi
• Nakamura, Kazufumi
• Ito, Hiroshi
• on behalf of the PEACH Investigators

Titel

Effect of Intensive and Standard Pitavastatin Treatment With or Without Eicosapentaenoic Acid on Progression of Coronary Artery Calcification Over 12 Months　― Prospective Multicenter Study

Ist Teil von

• Circulation Journal, 2018/01/25, Vol.82(2), pp.532-540

Ort / Verlag

Japan: The Japanese Circulation Society

Erscheinungsjahr

2018

Quelle

Elektronische Zeitschriftenbibliothek (Open access)

Beschreibungen/Notizen

• Background:The effect of lipid-lowering agents on progression of coronary artery calcification (CAC) remains unclear. We evaluated the effects of pitavastatin 2 mg/day (PIT2), pitavastatin 4 mg/day (PIT4), and PIT2 combined with eicosapentaenoic acid (PIT2+EPA) on CAC progression.Methods and Results:This prospective multicenter study in Japan included patients with an Agatston score of 1–999, hypercholesterolemia, and no evidence of cardiovascular disease. Patients were allocated into PIT2, PIT4, or PIT2+EPA groups. The primary outcome was the annual percent change in Agatston score in all patients. In total, 156 patients who had multi-detector row computed tomography without any artifacts were included in the primary analysis. Pitavastatin did not significantly reduce the annual progression rate of the Agatston score (40%; 95% CI: 19–61%). The annual progression rate of Agatston score in the PIT2 group was not significantly different from that in the PIT4 group (34% vs. 42%, respectively; P=0.88) or the PIT2+EPA group (34% vs. 44%, respectively; P=0.80). On post-hoc analysis the baseline ratio of low- to high-density lipoprotein cholesterol was a significant predictor of non-progression of Agatston score by pitavastatin (OR, 2.17; 95% CI: 1.10–44.12; P=0.02).Conclusions:Pitavastatin does not attenuate progression of CAC. Intensive pitavastatin treatment and standard treatment with EPA does not reduce progression of CAC compared with standard treatment.